About Us
Our Approach
Pipeline
- Overview
- Product Candidates
Clinical Trials
Investors & Media
Partnering
Careers
- Overview
- Current Openings
Contact Us

Email Alerts

About Us
Our Approach
Pipeline
- Overview
- Product Candidates
Clinical Trials
Investors & Media
Partnering
Careers
- Overview
- Current Openings
Contact Us

Overview
Leadership
Founders
Board of Directors
Scientific Advisory Board

Overview
Immuno-STAT Platform
Neo-STAT Platform
RDI-STAT Platform
What is IL-2?
Scientific Presentations & Publications

Overview
Product Candidates

Clinical Trials

Head and Neck Cancer (CUE-101)
Head and Neck Cancer (CUE-101 + Pembrolizumab)
Oropharyngeal Cancer (CUE-101 Neoadjuvant)

Investors & Media

Investor Overview Presentation & Kit
News
Events
Scientific Publications & Presentations
Stock Information
Financial Information
Corporate Governance
FAQs
Email Alerts

Overview
Oncology
Infectious and Autoimmune Diseases

Overview
Current Openings

Cue Biopharma
40 Guest Street
Boston, MA 02135

TEL 617-949-2680

Business Development: BD@cuebio.com
Media: media@cuebio.com
Investor Relations: IR@cuebio.com

Legal | Privacy | Cookies

© 2022 Cue Biopharma. All rights reserved.
The name Cue Biopharma, our logo, the tagline "Immune Responses, On Cue," the Cue Biologics name, "Immuno-STAT", "Immuno-STAT Biologics", "Neo-⁠STAT", and "RDI-STAT" are all trademarks of Cue Biopharma, Inc.

About Us
Our Approach
Pipeline
- Overview
- Product Candidates
Clinical Trials
Investors & Media
Partnering
Careers
- Overview
- Current Openings
Contact Us